<DOC>
	<DOCNO>NCT02493322</DOCNO>
	<brief_summary>The purpose study evaluate non-inferiority clinical efficacy two different drug association essential hypertension control .</brief_summary>
	<brief_title>Efficacy Safety Olmesartan Associated With Chlorthalidone Essential Arterial Hypertension Control</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Signed Consent patient ; Participants decompensated essential hypertension , classify stage 1 ( high high cardiovascular risk ) , stage 2 stage 3 accord Brazilian Society Cardiology ( 2010 ) , never treat indication drug combination treatment . Obs : The diagnosis may establish previous evaluation two blood pressure measure â‰¥ 140/90 mmHg , two month difference measurement Patients clinically significant disease investigator opinion participate study ; Secondary hypertension diagnosis blood pressure 190x100 mmHg screening/randomization visit ; Morbid obesity immunocompromised patient ; Participants great 10 mmHg difference measurement systolic diastolic blood pressure two arm ; Participants two upper limb ; Participants important electrocardiographic change ; Creatinine clearance le 60 mL /min ; History hypertensive emergency cardiovascular / moderate severe cerebrovascular event past 6 month ; Microalbuminuria urine sample great 30 mg/g ; Patients history hypersensitivity formula compound ; Pregnancy risk pregnancy lactate patient ; Participation clinical trial year prior study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>